LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP, representing investors of Thoratec Corporation (“Thoratec” or the “Company”) (NASDAQ:THOR), has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class (the “Class”) comprising all purchasers of Thoratec securities between April 29, 2010 and November 27, 2013, inclusive (the “Class Period”).
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, OR AT (212) 682-5340, OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Thoratec researches, develops, manufactures and markets medical devices for circulatory support and vascular graft applications. The Company’s products include a ventricular assist device, an implantable left ventricular heart assist device, a vascular access graft and a coronary artery bypass graft. The Complaint alleges that, throughout the Class Period, defendants failed to disclose that the Company’s HeartMate II Left Ventricular Assist Device had significant risk of pump thrombosis, causing numerous fatalities.
If you are a member of the Class described above, you may move the Court no later than March 25, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. If you wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.